Introducing trastuzumab as part of adjuvant therapy substantially changed the prognosis of HER2-positive breast cancer [3], and subsequent studies demonstrated that shorter treatment durations can provide non-inferior efficacy compared with the standard 12-month regimen [4]. The gene discussed is ERBB2; the disease is breast cancer.